Alignment Healthcare

Valuation Analysis

About the Company

Alignment Healthcare en bref

Alignment Healthcare (ALHC) is currently trading at 12,87 € with a market capitalization of 2,7 Md €. The trailing P/E ratio stands at 78.16x, with a forward P/E of 19.73x. The 52-week range spans from 11,25 € to 21,78 €; the current price is 40.9% below the yearly high. Year-over-year revenue growth stands at +31.6%. The net profit margin stands at 0.89%.

💰 Dividende

Alignment Healthcare currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

13 analystes évaluent Alignment Healthcare (ALHC) au consensus : Achat Fort. L'objectif de cours moyen est de 21,35 €, soit un potentiel de +65.76% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 13,87 € à 26,01 €.

Alignment Healthcare : la thèse d'investissement en détail

Alignment Healthcare (ALHC) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 31.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Strong Buy with an average price target implying roughly 65.76% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

With a net margin of just 0.89%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Short interest sits at 12.34% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 30.99x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 19.73x is meaningfully below the trailing 78.16x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 65.76% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to market-like volatility, elevated short interest (12.34%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Alignment Healthcare?

Compare top-rated brokers — low fees, trusted providers, fully regulated.